Update shared on 27 Nov 2025
Fair value Increased 0.61%Analysts have slightly increased their price target for Mycronic to SEK 218.67 from SEK 217.33. They cite improved revenue growth expectations and a marginally higher projected profit margin.
What's in the News
- Mycronic received an order for three mask writers from an existing customer in Asia, valued at USD 48-52 million. Deliveries are scheduled between 2026 and 2027 (Client Announcements).
- The company has received multiple orders for SLX mask writers from customers in Asia, each valued between USD 3-7 million. These orders reflect rising demand in the semiconductor industry (Client Announcements).
- Mycronic reaffirmed its sales guidance for 2025 and maintains expectations for net sales to reach SEK 7.5 billion (Corporate Guidance, New/Confirmed).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from SEK 217.33 to SEK 218.67.
- Discount Rate has decreased marginally from 6.39% to 6.38%.
- Revenue Growth expectation increased from 2.74% to 3.05%.
- Net Profit Margin forecast has edged higher from 21.72% to 21.87%.
- Future P/E has fallen modestly from 27.17x to 26.62x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.